Frontiers in Immunology, Год журнала: 2023, Номер 14
Опубликована: Дек. 4, 2023
Uveal melanoma (UV) is a rare and aggressive with poor 1-year survival. up to 50% of UV patients develop metastases, mainly the liver. Here, authors present 2-deoxy-2-[
Язык: Английский
Computers in Biology and Medicine, Год журнала: 2022, Номер 145, С. 105499 - 105499
Опубликована: Апрель 7, 2022
Язык: Английский
Процитировано
12
Japanese Journal of Radiology, Год журнала: 2022, Номер 41(5), С. 459 - 476
Опубликована: Дек. 28, 2022
Abstract [ 18 F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a well-established modality with high sensitivity for the diagnosis and staging of oncologic patients. FDG taken up by glucose transporter cell membrane becomes trapped within cell. In addition to malignant neoplasms, active inflammatory lesions some kinds benign tumors also accumulate FDG. Moreover, degree uptake into normal organs tissues depends on various physiological conditions, which affected medical procedures, treatments, drugs. To avoid misleading interpretations, it important recognize possible situations unexpected abnormal accumulation that mimic tumor lesions. this review, we present findings associated surgical or procedures treatments. Some reflect expected reaction treatment, show inflammation due prior procedures. Occasionally, FDG–PET visualizes other disorders are unrelated malignancy, may be adverse effects certain drugs patient taking. Careful review records detailed interviews patients thus necessary.
Язык: Английский
Процитировано
11
Cancer Imaging, Год журнала: 2022, Номер 22(1)
Опубликована: Дек. 20, 2022
Abstract Response assessment in the context of immunomodulatory treatments represents a major challenge for medical imaging community and requires multidisciplinary approach with involvement oncologists, radiologists, nuclear medicine specialists. There is evolving evidence that [ 18 F]FDG PET/CT useful diagnostic modality this purpose. The clinical indications for, principal aspects its standardization have been detailed recently published “ Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use during patients solid tumors version 1.0 ”. These recommendations arose from fruitful collaboration between international societies experts cancer treatment. In perspective, key elements initiative are reported, summarizing core guidelines radiologists physicians. Beyond previous guidelines, perspective adds further commentary how technology can advance development novel therapeutic approaches guide management individual patients.
Язык: Английский
Процитировано
10
The Quarterly Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2022, Номер 66(3)
Опубликована: Май 25, 2022
Despite their undisputed contribution to the management of various tumors and prolongation patient survival, immune checkpoint inhibitors (ICIs) exert effect at cost toxicity. In context activation host system triggered by ICIs, collateral, inflammatory side effects, commonly addressed as immune-related adverse events (irAEs) often occur. Early detection irAEs can be critical for adequate decisions on that may subsequently improve outcome. Moreover, emergence has been linked with antitumor elicited thus, identification potentially provide prognostic information. Although diagnosis is mainly clinical, some asymptomatic only diagnosed imaging modalities. At same time, radiological signs are not necessarily associated clinical symptoms, however, clinicians should alerted presence. Among modalities [18F]FDG PET/CT shown satisfying efficiency in response assessment monitoring ICIs' treatment, especially patients suffering from metastatic melanoma lung cancer. this context, also a valuable method surveillance during immunotherapy. This article aims review most common observed under immunotherapy summarize potential results linking PET ICIs.
Язык: Английский
Процитировано
9
Journal of Clinical Medicine, Год журнала: 2023, Номер 12(10), С. 3498 - 3498
Опубликована: Май 16, 2023
Immune checkpoint inhibitors are currently the standard of care for many advanced solid tumors, and they have been recently approved treatment relapsed/refractory Hodgkin lymphoma primary mediastinal B cell lymphoma. Assessments response to immunotherapy may be complicated by occurrence flare/pseudoprogression phenomenon, consisting initial tumor enlargement even appearance new lesions, followed a response, which initially indistinguishable from true progression. There efforts characterize capture patterns observed during immunotherapy, namely, pseudoprogression delayed several immune-related criteria proposed. Confirming progression on subsequent scan measuring total burden both common in criteria. Due peculiarity hematologic malignancies, lymphoma-specific developed (LYRIC), evaluated research studies comparison Lugano Classification. In this review work, we illustrate evolution lymphomas first CT-based development PET-based Classification, further refined take into account flare phenomenon encountered immunotherapy. We also describe additional contribution PET-derived volumetric parameters interpretation responses
Язык: Английский
Процитировано
5
PET Clinics, Год журнала: 2024, Номер 19(2), С. 231 - 248
Опубликована: Янв. 16, 2024
Язык: Английский
Процитировано
1
Cancer Biotherapy and Radiopharmaceuticals, Год журнала: 2023, Номер 38(4), С. 211 - 215
Опубликована: Фев. 2, 2023
In the past decade, implementation of immunotherapy with checkpoint inhibitors has determined a major change in management oncological patients. The challenges associated to new therapeutic regimen have promoted adapted criteria for response assessment interpret imaging findings and atypical patterns response. Parallel morphological criteria, also 18fluoro-deoxyglucose positron emission/computed tomography required novel approaches specific guidelines on how perform, interpret, report scan patients solid tumors under immune therapy. A summary novelties related joint international European Association Nuclear Medicine (EANM)/Society Molecular Imaging (SNMMI)/Australian New Zealand Society (ANZSNM) is provided herein elucidate most critical aspects image interpretation.
Язык: Английский
Процитировано
3
Journal for ImmunoTherapy of Cancer, Год журнала: 2022, Номер 10(11), С. e005092 - e005092
Опубликована: Ноя. 1, 2022
Twenty years after its initial introduction, Response Evaluation Criteria in Solid Tumors (RECIST) remains today a unique standardized tool allowing uniform objective evaluation of response solid tumors clinical trials across different treatment indications. Several attempts have been made to update or replace RECIST, but none realized the general traction uptake seen with RECIST. This communication provides an overview some challenges faced by RECIST rapidly changing oncology landscape, including incorporation PET 18 F-fluorodeoxyglucose tracer as for assessment and validation criteria use involving immunotherapeutics. The latter has mainly slow due lack data sharing. Work is ongoing try address this.We also aim share our view statistician representatives on Working Group what would be needed validate new imaging endpoints trial use, specific focus Whether this could lead altogether, depends changes being proposed. ultimate goal well defined, repeatable, confirmable standard provided today.
Язык: Английский
Процитировано
5
European Journal of Nuclear Medicine and Molecular Imaging, Год журнала: 2023, Номер 50(9), С. 2715 - 2726
Опубликована: Май 4, 2023
Immune checkpoint inhibitors (ICIs) are widely used in metastatic melanoma and dramatically alter the treatment of these patients. Given high cost potential toxicity, a reliable method for evaluating response is needed. In this study, we assessed tumor patients with treated ICIs using three modified criteria: PET Response Evaluation Criteria Immunotherapy (PERCIMT), Solid Tumors up to Five Lesions (PERCIST5), immunotherapy-modified (imPERCIST5).Ninety-one non-resectable stage IV who received were retrospectively enrolled study. Each patient had two [18F]FDG PET/CT scans performed before after ICI therapy. Responses at follow-up scan evaluated according PERCIMT, PERCIST5, imPERCIST5 criteria. Patients classified into four groups: complete metabolic (CMR), partial (PMR), progressive disease (PMD), stable (SMD). To assess "disease control rate," groups have been defined based on each criterion: CMR, PMR, SMD as "disease-controlled group (i.e., responders)" PMD "uncontrolled-disease non-responders)". The correspondence between by criteria clinical outcome was compared.The rates 40.7% 71.4%, 41.8% 50.5%, 54.9% 74.7% criteria, respectively. PERCIMT showed significantly different from that PERCIST5 (P < 0.001), whereas it not significant imPERCIST5. Overall survival longer responder than non-responder (PERCIMT: 2.48 versus 1.47 years, P = 0.003; PERCIST5: 2.57 1.81 years. 0.017). However, criterion, difference observed 0.12).Although appearance new lesions can be secondary an inflammatory indicative pseudoprogression, given higher rate true progression, should interpreted deliberately. Of appear provide more assessment correlates strongly overall survival.
Язык: Английский
Процитировано
2
Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 180, С. 117617 - 117617
Опубликована: Окт. 31, 2024
F-interleukin-2 based PET imaging of activated T cells serves as a potential tool for non-invasive response prediction, treatment evaluation, and patient stratification in cancer immune checkpoint therapy. Herein, we report the radiolabelling interleukin-2 (IL-2) with novel arginine selective bioconjugation reagent, 4-[
Язык: Английский
Процитировано
0